Publicaciones científicas

In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

16-mar-2022 | Revista: Molecular Therapy. Methods & Clinical Development

Rebeca Martinez-Turrillas  1   2 , Angel Martin-Mallo  3   2 , Saray Rodriguez-Diaz  1   2 , Natalia Zapata-Linares  1 , Paula Rodriguez-Marquez  3   2 , Patxi San Martin-Uriz  3   2 , Amaia Vilas-Zornoza  3   2   4 , María E Calleja-Cervantes  3   2 , Eduardo Salido  5   6 , Felipe Prosper  1   3   7   2   4 , Juan R Rodriguez-Madoz  1   3   2   4


Genome-editing strategies, especially CRISPR-Cas9 systems, have substantially increased the efficiency of innovative therapeutic approaches for monogenic diseases such as primary hyperoxalurias (PHs).

We have previously demonstrated that inhibition of glycolate oxidase using CRISPR-Cas9 systems represents a promising therapeutic option for PH type I (PH1).

Here, we extended our work evaluating the efficacy of liver-specific inhibition of lactate dehydrogenase (LDH), a key enzyme responsible for converting glyoxylate to oxalate; this strategy would not be limited to PH1, being applicable to other PH subtypes.

In this work, we demonstrate a liver-specific inhibition of LDH that resulted in a drastic reduction of LDH levels in the liver of PH1 and PH3 mice after a single-dose delivery of AAV8 vectors expressing the CRISPR-Cas9 system, resulting in reduced urine oxalate levels and kidney damage without signs of toxicity. Deep sequencing analysis revealed that this approach was safe and specific, with no off-targets detected in the liver of treated animals and no on-target/off-tissue events.

Altogether, our data provide evidence that in vivo genome editing using CRISPR-Cas9 systems would represent a valuable tool for improved therapeutic approaches for PH.

CITA DEL ARTÍCULO  Mol Ther Methods Clin Dev. 2022 Mar 16;25:137-146.  doi: 10.1016/j.omtm.2022.03.006. eCollection 2022 Jun 9.